Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Pulmonary/Respiratory Diseases | Cardiology/Vascular Diseases | Family Medicine
Clinical Trials: Pulmonary Arterial Hypertension
A listing of clinical trials currently looking for volunteers to enroll in Pulmonary Arterial Hypertension studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : The University of Alabama at Birmingham
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
Birmingham : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Birmingham : Cardiovascular Associates, PC
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Birmingham : Cardiovascular Associates, P.C.
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Birmingham : The University of Alabama at Birmingham
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
View More »
Mobile : University of South Alabama Medical Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Mobile : University of South Alabama
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Arizona
Phoenix : Arizona Pulmonary Specialists, Ltd.
ACT-293987 in Pulmonary Arterial Hypertension
Phoenix : Pulmonary Associates
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Phoenix : Arizona Pulmonary Specialists
Remodulin® to Oral Treprostinil Transition
Phoenix : Arizona Pulmonary Specialists
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Phoenix : Arizona Pulmonary Specialists, LTD
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
View More »
Tucson : University of Arizona
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Tucson : University of Arizona
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
Tuscon : The University of Arizona, Clinical and Translational Science (CATS) Research Center
ACT-293987 in Pulmonary Arterial Hypertension
California
Berkeley : Alta Bates Summit Medical Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Berkeley : Berkeley Cardiovascular Medical Group
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Beverly Hills : Cedars-Sinai Heart Institute
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Fountain Valley : Allianz Research Institute, Inc.
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Fountain Valley : Alliance Medical and Research Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
View More »
Fresno : University of California, San Francisco-Fresno
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Fresno : University California San Francisco
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Fresno : UCSF Fresno
Ventavis® Registry Protocol
La Jolla : University of California San Diego Medical Center (La Jolla)
ACT-293987 in Pulmonary Arterial Hypertension
La Jolla : UCSD Medical Center
Ventavis® Registry Protocol
Los Angeles : UCLA
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
Los Angeles : Cedars-Sinai Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Los Angeles : Ronald Reagan UCLA Medical Center
Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
Los Angeles : David Geffen School of Medicine at UCLA
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Los Angeles : West Los Angeles VA Healthcare Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Los Angeles : UCLA Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Los Angeles : University of Southern California
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Los Angeles : Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Los Angeles : David Geffen School of Medicine UCLA
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Los Angeles : VA Greater LA Health Care System-UCLA
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Los Angeles : West Los Angeles VA Healthcare Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Los Angeles : University of Southern California
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Los Angeles : David Geffen School of Medicine, UCLA
Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Los Angeles : UCLA
Ventavis® Registry Protocol
Oakland : Berkeley Cardiovascular Medical Group
Adult Congenital Heart Disease Registry (QuERI)
Sacramento : University of California, Davis, UC Davis Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Sacramento : University of California- Davis Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
San Francisco : University of California, San Francisco
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
San Francisco : University of CA, San Francisco
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
San Juan Capistrano : Paloma Medical Group
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
San Juan Capistrano : Paloma Medical Group
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Santa Barbara : Santa Barbara Cottage Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Santa Barbara : Santa Barbara Cottage Hospital
Ventavis® Registry Protocol
Stanford : Stanford University
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Stanford : Stanford Hospital and Clinics
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Torrance : LIU Center for Pulmonary Hypertension
ACT-293987 in Pulmonary Arterial Hypertension
Torrance : Los Angeles Biomedical Research Institute at Harbor-UCLA Med Ctr
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Torrance : Harbor-UCLA Medical Center
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
Colorado
Aurora : Children's Hospital Colorado
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Aurora : University of Colorado Denver
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Aurora : The Children's Hospital - Site 9102
Pulmonary Arterial Hypertension in Children
Aurora : University of Colorado Denver
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
View More »
Denver : National Jewish Medical and Research Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Denver : Children's Hospital Denver
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Littleton : South Denver Cardiology Associates PC
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Wheat Ridge : Western States Clinical Research, Inc.
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Wheatridge : Robert E. Benkert, M.D.P.C.
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Wheatridge : Western States Clinical Research
Ventavis® Registry Protocol
Connecticut
Delaware
Newark : Lung Health & Sleep Emhancement Center, LLC
ACT-293987 in Pulmonary Arterial Hypertension
Newark : Lung Health & Sleep Enhancement Center, LLC
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
District of Columbia
Washington : Georgetown University Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Washington : Children's National Medical Center - Site 9104
Pulmonary Arterial Hypertension in Children
Florida
Clearwater : CRWF
Do you have Pulmonary Hypertension?
Do you have Chronic Obstructive Pulmonary Disease (COPD)?
Tampa : CRWF, Inc.
Do you have Pulmonary Hypertension?
Do you have Chronic Obstructive Pulmonary Disease (COPD)?
View More »
Brandon : Bay Area Cardiology Assoc., P.A.
Adult Congenital Heart Disease Registry (QuERI)
Brandon : Bay Area Cardiology Research, P.A.
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Clearwater : Bay Area Chest Physicians
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Clearwater : St. Francis Sleep Allergy & Lung
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Fort Lauderdale : Broward Pulmonary and Sleep Specialists
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Gainesville : University of Florida
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Gainesville : University of Florida
Ventavis® Registry Protocol
Jacksonville : University of Florida, Jacksonville
Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching
Jacksonville : University of Florida College of Medicine
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Jacksonville : Pulmonary and Critical Care Associates
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Jacksonville : University of Florida College of Medicine Jacksonville
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Jacksonville : Mayo Clinic Jacksonville
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Miami : Miami Center for Cardiovascular Disease
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Miami Beach : Mount Sinai Medical Centre - Columbia University - Division of Cardiology
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Miami Beach : Mount Sinai Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Orlando : Central Florida Pulmonary Group, PA
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Orlando : Central Florida Pulmonary Group, P.A.
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Orlando : Orlando Heart Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Orlando : Orlando Heart Center
Ventavis® Registry Protocol
Orlando : Central Florida Pulmonary Group
Ventavis® Registry Protocol
Sarasota : Lung Associates of Sarasota
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Tampa : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Weston : Cleveland Clinic Florida
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Weston : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Weston : Cleveland Clinic Florida
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Weston : Cleveland Clinic Florida
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Weston : Cleveland Cliic Florida
Ventavis® Registry Protocol
Georgia
Atlanta : Emory University School of Medicine
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Augusta : Georgia Health Sciences University
ACT-293987 in Pulmonary Arterial Hypertension
Austell : Georgia Lung Associates, PC
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Georgia : Georgia Clinical Research
ACT-293987 in Pulmonary Arterial Hypertension
Illinois
Chicago : University of Chicago
Assessmet of Patients With PAH Right Ventricular Volume
Chicago : Northwestern University
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Chicago : University of Chicago
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Chicago : University of Illinois at Chicago
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Chicago : Northwestern University
Ranolazine and Pulmonary Hypertension
View More »
Chicago : Northwestern Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Chicago : Rush University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Chicago : University of Illinois at Chicago
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Oakbrook Terrace : Midwest Heart Foundation
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Indiana
Carmel : Clarian North Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Carmel : Indiana University Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Iowa
Iowa City : University of Iowa Hospitals & Clinics
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Iowa City : University of Iowa Hospitals & Clinics
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Iowa City : Mercy Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Iowa City : University of Iowa
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Kansas
Kansas City : University of Kansas Medical Center-Department of Pulmonary and Critical Care
ACT-293987 in Pulmonary Arterial Hypertension
Kansas City : University of Kansas Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Kansas City : The University of Kansas Medical Center
Ventavis® Registry Protocol
Kentucky
Louisville : Kentuckiana Pulmonary Associates
ACT-293987 in Pulmonary Arterial Hypertension
Louisville : Kentuckiana Pulmonary Associates
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Louisville : Kentuckiana Pulmonary Associates
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Louisville : Kentuckiana Pulmonary Associates
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Louisville : Kentuckiana Pulmonary Associates
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
View More »
Louisville : Kentuckiana Pulmonary Associates
Ventavis® Registry Protocol
Louisiana
New Orleans : LSU Health Science Center - New Orleans
ACT-293987 in Pulmonary Arterial Hypertension
New Orleans : LSUHSC-New Orleans
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
New Orleans : Ochsner Clinic
Ventavis® Registry Protocol
Maine
Portland : Maine Medical Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Maryland
Baltimore : Johns Hopkins University
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Baltimore : Johns Hopkins University School of Medicine
ACT-293987 in Pulmonary Arterial Hypertension
Baltimore : University of Maryland Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Baltimore : John Hopkins University Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Baltimore : Johns Hopkins University
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
View More »
Baltimore : University of Maryland Medical Centre
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Baltimore : Johns Hopkins University
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Baltimore : University of Maryland
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Baltimore : University of Maryland School of Medicine
Ventavis® Registry Protocol
Massachusetts
Boston : Boston University School of Medicine / Boston University Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Boston : Tufts Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Boston : Novartis Investigative Site
An Extension Study for Patients Who Participated in the CAMN107X2201 Study
Boston : Brigham and Women's Hospital
Assessmet of Patients With PAH Right Ventricular Volume
Boston : Massachusetts General Hospital
Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan
View More »
Boston : Tufts Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Boston : Boston University Medical School
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Boston : Tufts Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Boston : Brigham & Women's Hospital -Pulmonary and Critical Care Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Boston : Brigham and Women's Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Boston : Tufts - New England Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Worcester : University of Massachussetts Memorial Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Michigan
Ann Arbor : University of Michigan
ACT-293987 in Pulmonary Arterial Hypertension
Ann Arbor : University of Michigan
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Ann Arbor : University of Michigan-Scleroderma Program
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Detroit : Henry Ford Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Detroit : Henry Ford Health System
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
View More »
Grand Rapids : Spectrum Health
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Troy : Beaumont Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Troy : William Beaumont Hospital - Troy
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Troy : William Beaumont Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Minnesota
Minneapolis : University of Minnesota
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Minneapolis : Hennepin County Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Rochester : Mayo Clinic
ACT-293987 in Pulmonary Arterial Hypertension
Rochester : Mayo Clinic
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
Rochester : Mayo Clinic
Assessmet of Patients With PAH Right Ventricular Volume
View More »
Rochester : Mayo Clinic
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Missouri
St. Louis : Washington University School of Medicine
ACT-293987 in Pulmonary Arterial Hypertension
St. Louis : Washington University School of Medicine
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
St. Louis : Washington University School of Medicine
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
St. Louis : Washington University School of Medicine
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
St. Louis : St. Louis University
Ventavis® Registry Protocol
Nebraska
Lincoln : Nebraska Pulmonary Specialties, LLC
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Lincoln : Nebraska Pulmonary Specialties, LLC
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Lincoln : Nebraska Pulmonary Specialties
Ventavis® Registry Protocol
Omaha : Creighton University Medical Centre - Pulmonary, Critical Care and Sleep Medicine Division
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Omaha : University of Nebraska Medical Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Nevada
New Hampshire
Lebanon : Dartmouth-Hitchcock Medical Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
New Jersey
Bloomfield : Michael Schwarz, MDFACC
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Hackensack : Hackensack University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
New Brunswick : University of Medicine and Dentistry of New Jersey
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
New Brunswick : UMDNJ - Robert Wood Johnson Medical Center Clinical Research Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Newark : Newark Beth Isreal Medical Center-Department of Pulmonary Medicine
ACT-293987 in Pulmonary Arterial Hypertension
View More »
Newark : Barnabas Health Newark Beth Israel Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Newark : Pulmonary Hypertension & Lung Transplant Program Newark Beth Israel Medical Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Newark : University of Medicine and Dentistry of New Jersey
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Newark : Newark Beth Israel Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Newark : Newark Beth Israel Medical Center
Ventavis® Registry Protocol
New York
Lake Success : Biomedical Research Alliance of New York
Scleroderma and Pulmonary Hypertension (PHT) - Adults
New Hyde Park : Biomedical Research Alliance of New York
Pulmonary Arterial Hypertension (PAH) - Adults
View More »
Albany : Center for Rheumatology
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Bronx : Montefiore Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Bronx : Montefiore Medical Center
Ventavis® Registry Protocol
Buffalo : Kaleida Health/Buffalo General Hospital
Ventavis® Registry Protocol
Islandia : Stony Brook University Medical Center Department of Medicine
ACT-293987 in Pulmonary Arterial Hypertension
Islandia : SUNY Stony Brook University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Mineola : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Mineola : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Mineola : Winthrop Pulmonary Associates
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Mineola : Winthrop University Hospital
Ventavis® Registry Protocol
New Hyde Park : North Shore Long Island Jewish Medical Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
New Hyde Park : North Shore - Long Island Jewish Health System
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
New Hyde Park : North Shore University - LIJ Medical Center
Ventavis® Registry Protocol
New York : Columbia University Medical Center, Pediatric Cardiology
ACT-293987 in Pulmonary Arterial Hypertension
New York : Beth Israel Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
New York : Cornell University
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
New York : Hospital for Special Surgery
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
New York : Columbia University Medical Center Children's Hospital of New York Presbyterian - Site 9101
Pulmonary Arterial Hypertension in Children
New York : Columbia University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
New York : St. Luke's-Roosevelt Hospital Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
New York : Beth Israel Medical Center
Ventavis® Registry Protocol
Rochester : University of Rochester
Remodulin® to Oral Treprostinil Transition
Rochester : Mary M Parkes Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Rochester : Mary M. Parkes Asthma Center, University of Rochester
The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
Syracuse : Pulmonary Health Physicians
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Syracuse : Pulmonary Health Physicians
Ventavis® Registry Protocol
North Carolina
Charlotte : American Health Research
6 week Study for Patients with Pulmonary Hypertension Associated with COPD
View More »
Chapel Hill : University of North Carolina at Chapel Hill
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Durham : Duke University Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Pinehurst : Pinehurst Medical Clinic
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Winston Salem : Wake Forest University Phyisicans Clinic/Pulmonary
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Winston-Salem : Wake Forest University Health Sciences
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Ohio
Akron : Akron General Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Cincinnati : University of Cincinnati
ACT-293987 in Pulmonary Arterial Hypertension
Cincinnati : The Lindner Clinical Trial Center
ACT-293987 in Pulmonary Arterial Hypertension
Cincinnati : UC Health/University of Cincinnati
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Cincinnati : University of Cincinnati Pulmonary Critical Care & Sleep Medicine
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
View More »
Cincinnati : The Christ Hospital Heart & Vascular Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Cincinnati : The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Cincinnati : University of Cincinnati
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Cincinnati : University of Cincinnati
Ventavis® Registry Protocol
Cleveland : Novartis Investigative Site
An Extension Study for Patients Who Participated in the CAMN107X2201 Study
Cleveland : Cleveland Clinic
Assessmet of Patients With PAH Right Ventricular Volume
Cleveland : University Hospitals Case Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Cleveland : Cleveland Clinic
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Cleveland : Cleveland Clinic
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Cleveland : University Hospitals of Cleveland
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Colombus : The Ohio State University Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Columbus : Ohio State University Martha Morehouse Medical Pavillion
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Columbus : Ohio State University, Martha Morehouse Medical Plaza
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Columbus : Davis Heart and Lung Research Institute
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Columbus : The Ohio State University Medical Center
Ventavis® Registry Protocol
Dayton : Dayton Respiratory Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Fairfield : Mercy Fairfield Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Oregon
Bend : Heart Center Cardiology
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Portland : Legacy Medical Group - Pulmonary Clinic
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Portland : Legacy Pulmonary Northwest
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Portland : Oregon Clinic, PC
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Portland : OHSU-Oregon Health and Science University
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Pennsylvania
Doylestown : Central Bucks Specialists
ACT-293987 in Pulmonary Arterial Hypertension
Doylestown : Central Bucks Specialists
Adult Congenital Heart Disease Registry (QuERI)
Doylestown : Central Bucks Specialists - The Pavilion at Doylestown Hospital
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Hershey : Penn State Milton S. Hershey Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
View More »
Philadelphia : Penn Presbyterian Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Philadelphia : Temple University Hospital
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Philadelphia : Pulmonary Vascular Disease Program, Penn Presbyterian Medical Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Philadelphia : Pulmonary Hypertension Program, Cardiology, Children's Hospial of Philadelphia
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Philadelphia : Temple University Hospital
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Philadelphia : Temple University
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Philadelphia : Thomas Jefferson University
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Philadelphia : Children's Hospital of Philadelphia
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Philadelphia : University of Pennsylvania Health System
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Pittsburgh : Allegheny General Hospital
Assessmet of Patients With PAH Right Ventricular Volume
Pittsburgh : Allegheny Singer Research Institute/Allegheny General Hospital
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Pittsburgh : University of Pittsburgh
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Pittsburgh : University of Pittsburgh Medical Center
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Pittsburgh : Allegheny General Hospital
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Pittsburgh : Allegheny General Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Pittsburgh : University of Pittsburgh Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Wyomissing : Respiratory Specialists
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Wyomissing : Berks Schuylkill Respiratory Specialists, Ltd.
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
York : Wellspan Lung, Sleep and Critical Care
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Rhode Island
Providence : Rhode Island Hospital
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Providence : Rhode Island Hospital
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Providence : Rhode Island Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
South Carolina
Charleston : Medical University of South Carolina
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Charleston : Medical University of South Carolina
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Lexington : Lexington Pulmonary and Critical Care
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
South Dakota
Sious Falls : Sioux Falls Cardiovascular PC
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Tennessee
Chattanooga : MD Total Care, PLLC
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Knoxville : Statcare Pulmonary Consultants
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Knoxville : Summit Medical Group
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Nashville : Vanderbilt Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Nashville : Vanderbilt University Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Texas
Dallas : UT Southwestern Medical Center at Dallas
ACT-293987 in Pulmonary Arterial Hypertension
Dallas : UT Southwestern Medical Center
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
Dallas : University of Texas Southwestern Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Dallas : UT Southwestern Medical Center
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Dallas : UT Southwestern Medical Center
Ventavis® Registry Protocol
View More »
El Paso : El Paso Respiratory and Sleep Consultants
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Houston : University of Texas-Houston Health Center Department of Pulmonary & Critical Care
ACT-293987 in Pulmonary Arterial Hypertension
Houston : Baylor College of Medicine
ACT-293987 in Pulmonary Arterial Hypertension
Houston : Baylor
Assessmet of Patients With PAH Right Ventricular Volume
Houston : Baylor College of Medicine
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Houston : The University of Texas Health Science Center
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Houston : Texas Children's Hospital - Department of Cardiology - Site 9107
Pulmonary Arterial Hypertension in Children
Houston : Baylor College of Medicine
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Houston : UT Health - University of Texas Houston
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Houston : Baylor College of Medicine
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Houston : Texas Children's Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Houston : University of Texas Health Science Center at Houston
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Houston : Baylore College of Medicine
Ventavis® Registry Protocol
San Antonio : Methodist Healthcare System of San Antonio
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
San Antonio : University of Texas Health Science Center at San Antonio
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Utah
Murray : Intermountain Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Provo : Central Utah Clinic
Ventavis® Registry Protocol
Salt Lake City : University of Utah
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
Salt Lake City : University of Utah
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Virginia
Falls Church : IHVI, Advanced Lung Disease and Transplant Clinic
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Falls Church : Inova Fairfax Hospital
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Lynchburg : The Cardiovascular Group Central
Adult Congenital Heart Disease Registry (QuERI)
Norfolk : Sentara Medical Group
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Norfolk : Sentara Cardiovascular Research Institute
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
View More »
Norfolk : Sentara Cardiovascular Research Institute
Trial of the Early Combination of Oral Treprostinil With a PDE-5 Inhibitor or ERA in Subjects With Pulmonary Arterial Hypertension
Norfolk : Sentara Norfolk General Hospital
Ventavis® Registry Protocol
Richmond : Virginia Commonwealth University
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension
Washington
Wisconsin
Madison : University of Wisconsin
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
Madison : University of Wisconsin Hospital-Department of Medicine
ACT-293987 in Pulmonary Arterial Hypertension
Milwaukee : St. Luke's Medical Center
ACT-293987 in Pulmonary Arterial Hypertension
Milwaukee : Aurora St. Luke's Medical Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Milwaukee : The Medical College of Wisconsin
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
View More »
Milwaukee : Aurora St. Luke's Medical Center
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled NITROsyl
Milwaukee : Aurora Health Care
Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Milwaukee : St. Luke's Medical Center
Ventavis® Registry Protocol
Argentina
Australia
Adelaide : Royal Adelaide Hospital, Cardiovascular Investigation Unit (CVIU)
ACT-293987 in Pulmonary Arterial Hypertension
Bedford Park : Flinders Medical Centre, Pulmonary Hypertension, c/- Cardiology
ACT-293987 in Pulmonary Arterial Hypertension
Chermside : Prince Charles Hospital Lung Transplant, Thoracic Department
ACT-293987 in Pulmonary Arterial Hypertension
Darlinghurst : St. Vincent's Hospital / Heart and Lung Transplant Unit
ACT-293987 in Pulmonary Arterial Hypertension
Darlinghurst : Pfizer Investigational Site
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
View More »
Darlinghurst : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Darlinghurst : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Fitzroy : St Vincent's Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Hobart : Royal Hobart Hospital, Centre for Clinical Research
ACT-293987 in Pulmonary Arterial Hypertension
New Lambton : John Hunter Hospital Autoimmune Resource and Research Centre
ACT-293987 in Pulmonary Arterial Hypertension
Parkville : Royal Melbourne Hospital, Department of Respiratory and Sleep Medicine
ACT-293987 in Pulmonary Arterial Hypertension
Parkville : Royal Children's Hospital Melbourne, Cardiology - Site 5001
Pulmonary Arterial Hypertension in Children
Perth : Royal Perth Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Austria
Graz : Medizinische Universität Graz
ACT-293987 in Pulmonary Arterial Hypertension
Vienna : Medical University of Vienna and AKH Cardiology
ACT-293987 in Pulmonary Arterial Hypertension
Belarus
Belgium
Brussels : Ulb Erasme, Cardiology
ACT-293987 in Pulmonary Arterial Hypertension
Bruxelles : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Leuven : University Hospital Gasthuisberg - Pneumologie
ACT-293987 in Pulmonary Arterial Hypertension
Leuven : UZ Gasthuisberg
Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension
Leuven : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
View More »
Leuven : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Canada
Calgary : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Calgary : Peter Lougheed Center
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Edmonton : University of Alberta Hospital - Children's Centre
ACT-293987 in Pulmonary Arterial Hypertension
Edmonton : ABACUS - University of Alberta Hospitals
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
London : London Health Sciences Centre
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
View More »
Montreal : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Montreal : Hopital General Juif (Jewish General Hospital)
ACT-293987 in Pulmonary Arterial Hypertension
Montreal : Sir Mortimer B Davis Jewish General Hospital
Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension
Ottawa : University of Ottawa Heart Institute
ACT-293987 in Pulmonary Arterial Hypertension
Quebec City : Institut Universitaire de Cardiologie et de Pneumologie de Quebec
ACT-293987 in Pulmonary Arterial Hypertension
Tononto : Toronto General Hospital
Assessmet of Patients With PAH Right Ventricular Volume
Toronto : University Health Network
ACT-293987 in Pulmonary Arterial Hypertension
Toronto : University Health Network, Toronto TGH - 10 EN - 220
Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension
Vancouver : Vancouver General Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Winnipeg : Health Sciences Centre
ACT-293987 in Pulmonary Arterial Hypertension
Chile
China
Colombia
Bogota : Fundacion Cardio Infantil
ACT-293987 in Pulmonary Arterial Hypertension
Bogota : Fundacion Clinica Shaio
ACT-293987 in Pulmonary Arterial Hypertension
Czech Republic
Denmark
France
Bron cedex : Hosp Pradel Lyon - Dpt Pneumology
ACT-293987 in Pulmonary Arterial Hypertension
Caen : Centre Hospitalier Universitaire
Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension
Caen Cedex : Hosp Cote de Nacre - Dpt Pneumology
ACT-293987 in Pulmonary Arterial Hypertension
Clamart : Hosp A. Beclere - Dept Pulmo & Resp Intensive Care
ACT-293987 in Pulmonary Arterial Hypertension
Clamart Cedex : Hôpital Antoine Béclère
Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension
View More »
Lille : Pfizer Investigational Site
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Lille Cedex : Hosp Huriez - Dpt Internal Medecine
ACT-293987 in Pulmonary Arterial Hypertension
Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Paris : Hopital Necker-Enfants Malades, Service de Cardiologie Pédiatrique - Site 2201
Pulmonary Arterial Hypertension in Children
Strasbourg : Hosp Civil - Dpt Pneumology
ACT-293987 in Pulmonary Arterial Hypertension
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Toulouse : CHU de Toulouse - Hôpital des Enfants, Service de Cardiologie Pédiatrique - Site 2202
Pulmonary Arterial Hypertension in Children
Toulouse Cedex 9 : Hosp Larrey - Dpt Pneumology
ACT-293987 in Pulmonary Arterial Hypertension
Germany
Berlin : DRK Kliniken Köpenick
ACT-293987 in Pulmonary Arterial Hypertension
Berlin : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Berlin : Deutsches Herzzentrum Kinderkardiologie - Site 1401
Pulmonary Arterial Hypertension in Children
Coburg : Pfizer Investigational Site
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Dresden : Universitätsklinikum Carl Gustav Carus, Medizinische Klinik1-Pneumologie/MK1-A13
ACT-293987 in Pulmonary Arterial Hypertension
View More »
Dresden : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Essen : Pfizer Investigational Site
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Giessen : "Justus-Liebig-Universität Gießen Zentrum für Innere Medizin Medizinische Klinik II"
ACT-293987 in Pulmonary Arterial Hypertension
Giessen : Justus-Liebig-Universität Giessen, Kinderherzzentrum - Site 1403
Pulmonary Arterial Hypertension in Children
Greifswald : Universität Greifswald / Klinik für Innere Medizin B
ACT-293987 in Pulmonary Arterial Hypertension
Greifswald : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Hamburg : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Hamburg : Department of Respiratory Medicine, University Medical Center Hamburg-Eppendorf
Endothelial Function in Patients With Pulmonary Arterial Hypertension
Hannover : Medizinische Hochschule Hannover / Klinik für Pneumologie
ACT-293987 in Pulmonary Arterial Hypertension
Hannover : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Hannover : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Heidelberg : Thoraxklinik am Universitätsklinikum Heidelberg
ACT-293987 in Pulmonary Arterial Hypertension
Heidelberg : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Homburg : Pfizer Investigational Site
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Köln : "Universitätsklinikum Köln Herzzentrum / Klinik III für Innere Medizin (Kardiologie, Pneumologie, Angiologie und Intensivmedizin)"
ACT-293987 in Pulmonary Arterial Hypertension
Köln : Novartis Investigative Site
An Extension Study for Patients Who Participated in the CAMN107X2201 Study
Leipzig : Praxis für Pneumologie und Allergologie
ACT-293987 in Pulmonary Arterial Hypertension
Löwenstein : Klinik Löwenstein gGmbH, Medizinische Klinik 1, Pneumologie - Kardiologie
ACT-293987 in Pulmonary Arterial Hypertension
Marburg : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Nuernberg : Pfizer Investigational Site
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Regensburg : Universitätsklinkum Regensburg / Innere Medizin II
ACT-293987 in Pulmonary Arterial Hypertension
Wuerzburg : Pfizer Investigational Site
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Greece
Alexandroupoli : University Hospital of Alexandroupoli
ACT-293987 in Pulmonary Arterial Hypertension
Athens : Onasseio Cardiosurgical Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Haidari : Pfizer Investigational Site
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
Thessaloniki : University Hospital of Ahepa
ACT-293987 in Pulmonary Arterial Hypertension
Hungary
India
Ahmedabad : Sanjivani Hospitals - Department of Cardiology
ACT-293987 in Pulmonary Arterial Hypertension
Chennai : Apollo Hospitals, Chennai
ACT-293987 in Pulmonary Arterial Hypertension
Chennai : Frontier Lifeline Hospitals, Dr KM Cherian Heart Foundation, Chennai
ACT-293987 in Pulmonary Arterial Hypertension
Hyderabad : Pfizer Investigational Site
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Hyderabad : CARE Hospitals Nampally, Cardiology Dep. Hyderabad
ACT-293987 in Pulmonary Arterial Hypertension
View More »
Hyderabad : CARE Hospitals, Cardiology Dep. Hyderabad - Site 5302
Pulmonary Arterial Hypertension in Children
Kochi : Pfizer Investigational Site
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
New Dehli : Indraprashta Apollo Hospitals, Pediatric Cardiology - Site 5303
Pulmonary Arterial Hypertension in Children
New Delhi : Apollo Indraprastha Hospitals
ACT-293987 in Pulmonary Arterial Hypertension
Ireland
Dublin : Mater Miscordiae University Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Israel
Italy
Japan
Azumino : Nagano Children's Hospital
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Fukuoka : Fukuoka Children's Hospital & Medical Center for Infectious Diseases
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Shinjyuku-ku : Tokyo Women's Medical University Hospital
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Shizuoka : Shizuoka Children's Hospital
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Suita : Osaka University Hospital
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
View More »
Tokyo : Toho Daigaku Iryou Center Ohmori
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Yokohama : Kanagawa Children's Medical Center
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Korea, Republic of
Incheon : Gil Medical Centre
ACT-293987 in Pulmonary Arterial Hypertension
Seoul : Yonsei University Health System Dept of Cardiology
ACT-293987 in Pulmonary Arterial Hypertension
Seoul : Seoul Nathional University Hospital
ACT-293987 in Pulmonary Arterial Hypertension
Seoul : Samsung Medical Center, Division of Cardiology
ACT-293987 in Pulmonary Arterial Hypertension
Seoul : "The Catholic University of Korea, Seoul St. Mary's Hospital Department of Cardiology"
ACT-293987 in Pulmonary Arterial Hypertension
View More »
Seoul : Seoul National University Hospital
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
Seoul : Samsung Medical Center
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
Seoul : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Special City of Seoul : Severance Hospital, Yonsei University Health System
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
Lithuania
Vilnius : Novartis Investigative Site
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension
Vilnius : Novartis Investigative Site
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Patients
Malaysia
Mexico
Netherlands
Peru
Poland
Gdansk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Gdansk : Uniwersyteckie Centrum Kliniczne Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca - Site 3604
Pulmonary Arterial Hypertension in Children
Gdańsk : "Uniwersyteckie Centrum Kliniczne II Klinika Kardiologii i Elektroterapii Serca"
ACT-293987 in Pulmonary Arterial Hypertension
Krakow : "Instytut Kardiologii Collegium Medium UJ Krakowski Szpital Specjalistyczny im Jana Pawła II Klinika Chorób Serca i Naczyń"
ACT-293987 in Pulmonary Arterial Hypertension
Łódź : "Wojewódzki Specjalistyczny Szpital im. dr Władysława Biegańskiego Oddział Kardiologiczny, II Katedra i Klinika Kardiologii UM"
ACT-293987 in Pulmonary Arterial Hypertension
View More »
Many Locations :
Efficacy of Ventavis Used in Real-life Setting.
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Warszawa : "Instytut Gruźlicy i Chorób Płuc Klinika Chorób Wewnętrznych Klatki Piersiowej"
ACT-293987 in Pulmonary Arterial Hypertension
Warszawa : Instytut Pomnik - Centrum Zdrowia Dziecka Klinika Kardiologii Dziecięcej - Site 3601
Pulmonary Arterial Hypertension in Children
Warzawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Wroclaw : Wojewódzki Szpital Specjalistyczny we Wrocławiu Oddział Kardiologii Dziecięcej z pododdziałem Intensywnego Nadzoru Kardiologicznego - Site 3605
Pulmonary Arterial Hypertension in Children
Puerto Rico
San Juan : PAH Clinic CPR at Auxilio Mutuo
Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Romania
Russian Federation
Serbia
Singapore
Singapore : National Heart Centre (NHC) Singapore
ACT-293987 in Pulmonary Arterial Hypertension
Singapore : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Slovakia
South Africa
Spain
Barcelona : Clinic-Barcelona
ACT-293987 in Pulmonary Arterial Hypertension
Barcelona : Hosp Vall D'Hebron - Barcelona - Pneumology
ACT-293987 in Pulmonary Arterial Hypertension
Barcelona : Hospital Vall d'Hebron
Epoprostenol for Injection (EFI) / ACT-385781A - Pulmonary Arterial Hypertension
Madrid : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
Madrid : Hospital 12 Octubre
ACT-293987 in Pulmonary Arterial Hypertension
View More »
Many Locations :
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
Sweden
Switzerland
Basel : University Hospital Basel Division of Pneumology
ACT-293987 in Pulmonary Arterial Hypertension
Bern : Universitätsspital Bern, Clinic for Pneumology (Inselspital)
ACT-293987 in Pulmonary Arterial Hypertension
Genève 14 : HUG Hôpitaux Universitaires de Genève; Pneumology, PAH
ACT-293987 in Pulmonary Arterial Hypertension
Lausanne : "Centre Hospitalier Universitaire Vaudois University Hospital Lausanne, Pulmology Department"
ACT-293987 in Pulmonary Arterial Hypertension
St. Gallen : Kantonsspital St. Gallen Klinik für Pneumologie
ACT-293987 in Pulmonary Arterial Hypertension
View More »
St. Gallen : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Zurich : Novartis Investigative Site
Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Taiwan
Thailand
Turkey
Ukraine
United Kingdom
